questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Mécanismes moléculaires de l'action pharmacologique
Inducteurs des enzymes du cytochrome P-450
Inducteurs du cytochrome P-450 CYP2D6
Inducteurs du cytochrome P-450 CYP2D6 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Cytochrome P-450 CYP2D6
Inducteurs
Tests génétiques
Cytochrome P-450 CYP2D6
Efficacité des médicaments
Cytochrome P-450 CYP2D6
Cytochrome P-450 CYP2D6
Métabolisme des médicaments
Rifampicine
Carbamazépine
Symptômes
5
Symptômes
Cytochrome P-450 CYP2D6
Concentration plasmatique
Efficacité des médicaments
Effets secondaires
Cytochrome P-450 CYP2D6
Non-réponse au traitement
Cytochrome P-450 CYP2D6
Intoxication
Cytochrome P-450 CYP2D6
Prévention
5
Prévention
Interactions médicamenteuses
Éducation des patients
Cytochrome P-450 CYP2D6
Antécédents médicamenteux
Interactions médicamenteuses
Surveillance médicale
Cytochrome P-450 CYP2D6
Lignes directrices
Interactions médicamenteuses
Traitements
5
Ajustement de dose
Cytochrome P-450 CYP2D6
Inhibiteurs
Cytochrome P-450 CYP2D6
Antidépresseurs
Antipsychotiques
Médicaments non inducteurs
Cytochrome P-450 CYP2D6
Suivi médical
Efficacité des médicaments
Complications
5
Complications
Efficacité thérapeutique
Hospitalisations
Cytochrome P-450 CYP2D6
Risques
Interactions médicamenteuses
Gestion des complications
Cytochrome P-450 CYP2D6
Complications à long terme
Métabolisme
Facteurs de risque
5
Facteurs de risque
Variations génétiques
Âge
Cytochrome P-450 CYP2D6
Habitudes de vie
Cytochrome P-450 CYP2D6
Prédispositions génétiques
Cytochrome P-450 CYP2D6
Interactions médicamenteuses
Cytochrome P-450 CYP2D6
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inducteurs du cytochrome P-450 CYP2D6 : Questions médicales les plus fréquentes",
"headline": "Inducteurs du cytochrome P-450 CYP2D6 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inducteurs du cytochrome P-450 CYP2D6 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-30",
"dateModified": "2025-02-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2D6"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inducteurs des enzymes du cytochrome P-450",
"url": "https://questionsmedicales.fr/mesh/D065693",
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs des enzymes du cytochrome P-450",
"code": {
"@type": "MedicalCode",
"code": "D065693",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.349"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2D6",
"alternateName": "Cytochrome P-450 CYP2D6 Inducers",
"code": {
"@type": "MedicalCode",
"code": "D065699",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Andrea Gaedigk",
"url": "https://questionsmedicales.fr/author/Andrea%20Gaedigk",
"affiliation": {
"@type": "Organization",
"name": "Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA."
}
},
{
"@type": "Person",
"name": "J Steven Leeder",
"url": "https://questionsmedicales.fr/author/J%20Steven%20Leeder",
"affiliation": {
"@type": "Organization",
"name": "Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA."
}
},
{
"@type": "Person",
"name": "Vincent S Staggs",
"url": "https://questionsmedicales.fr/author/Vincent%20S%20Staggs",
"affiliation": {
"@type": "Organization",
"name": "School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA."
}
},
{
"@type": "Person",
"name": "Robin E Pearce",
"url": "https://questionsmedicales.fr/author/Robin%20E%20Pearce",
"affiliation": {
"@type": "Organization",
"name": "Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA."
}
},
{
"@type": "Person",
"name": "Yan Pan",
"url": "https://questionsmedicales.fr/author/Yan%20Pan",
"affiliation": {
"@type": "Organization",
"name": "Department of Biomedical Science, University of Nottingham, Malaysia Campus, Semenyih, Selangor, Malaysia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cognitive profile in functional disorders.",
"datePublished": "2023-11-30",
"url": "https://questionsmedicales.fr/article/37889124",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/13546805.2023.2275336"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Uric acid, cognitive disorders, neurodegeneration].",
"datePublished": "2024-06-03",
"url": "https://questionsmedicales.fr/article/38829804",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.26442/00403660.2024.05.202698"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cognitive subgroups and their longitudinal trajectories in bipolar disorder.",
"datePublished": "2022-06-25",
"url": "https://questionsmedicales.fr/article/35690884",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/acps.13460"
}
},
{
"@type": "ScholarlyArticle",
"name": "An evolutionary account of impairment of self in cognitive disorders.",
"datePublished": "2022-09-30",
"url": "https://questionsmedicales.fr/article/36180662",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10339-022-01110-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cognitive impairment in bipolar disorder in comparison to mild cognitive impairment and dementia: a systematic review.",
"datePublished": "2023-02-20",
"url": "https://questionsmedicales.fr/article/34374270",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.47626/2237-6089-2021-0300"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Inducteurs des enzymes du cytochrome P-450",
"item": "https://questionsmedicales.fr/mesh/D065693"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inducteurs du cytochrome P-450 CYP2D6",
"item": "https://questionsmedicales.fr/mesh/D065699"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inducteurs du cytochrome P-450 CYP2D6 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Comment identifier un inducteur du CYP2D6 ?\nQuels tests sont utilisés pour évaluer l'activité du CYP2D6 ?\nQuels signes indiquent une induction du CYP2D6 ?\nPeut-on mesurer l'activité du CYP2D6 ?\nQuels médicaments sont des inducteurs connus ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Cognition+Disorders#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Quels symptômes peuvent résulter d'une induction du CYP2D6 ?\nComment l'induction affecte-t-elle les médicaments ?\nY a-t-il des effets secondaires liés aux inducteurs ?\nQuels signes cliniques peuvent alerter sur une induction ?\nL'induction peut-elle causer des symptômes d'intoxication ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Cognition+Disorders#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Comment prévenir l'induction du CYP2D6 ?\nLes patients doivent-ils être informés des inducteurs ?\nQuelles précautions prendre lors de la prescription ?\nLes médecins doivent-ils surveiller les inducteurs ?\nY a-t-il des recommandations pour les prescripteurs ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Cognition+Disorders#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Comment gérer l'induction du CYP2D6 ?\nPeut-on utiliser des inhibiteurs du CYP2D6 ?\nQuels médicaments sont souvent ajustés ?\nY a-t-il des alternatives aux inducteurs ?\nComment surveiller l'efficacité du traitement ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Cognition+Disorders#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Quelles complications peuvent survenir avec l'induction ?\nL'induction peut-elle entraîner des hospitalisations ?\nQuels risques sont associés à l'induction ?\nComment gérer les complications liées à l'induction ?\nY a-t-il des complications à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Cognition+Disorders#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Quels sont les facteurs de risque d'induction ?\nL'âge influence-t-il l'induction du CYP2D6 ?\nLes habitudes de vie jouent-elles un rôle ?\nY a-t-il des prédispositions génétiques ?\nLes interactions médicamenteuses sont-elles un facteur ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Cognition+Disorders#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un inducteur du CYP2D6 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par l'analyse des médicaments et leur effet sur le métabolisme."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du CYP2D6 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des dosages de médicaments peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une induction du CYP2D6 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une diminution de l'efficacité des médicaments métabolisés par CYP2D6 peut indiquer une induction."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'activité du CYP2D6 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activité peut être mesurée par des tests de métabolisme de médicaments spécifiques."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont des inducteurs connus ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme la rifampicine et la carbamazépine sont des inducteurs connus."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent résulter d'une induction du CYP2D6 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une induction peut entraîner une réduction de l'efficacité des médicaments, causant des symptômes de maladie."
}
},
{
"@type": "Question",
"name": "Comment l'induction affecte-t-elle les médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut réduire la concentration plasmatique des médicaments, diminuant leur effet thérapeutique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires liés aux inducteurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires peuvent survenir si les médicaments perdent leur efficacité."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques peuvent alerter sur une induction ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de non-réponse au traitement peuvent alerter sur une induction du CYP2D6."
}
},
{
"@type": "Question",
"name": "L'induction peut-elle causer des symptômes d'intoxication ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, si des médicaments sont sous-dosés, cela peut entraîner des symptômes d'intoxication."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'induction du CYP2D6 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les inducteurs connus et surveiller les interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être informés des inducteurs ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation des patients sur les inducteurs est cruciale pour éviter des complications."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre lors de la prescription ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluer les antécédents médicamenteux et les interactions potentielles avant de prescrire."
}
},
{
"@type": "Question",
"name": "Les médecins doivent-ils surveiller les inducteurs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance régulière des médicaments inducteurs est recommandée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les prescripteurs ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des lignes directrices existent pour éviter les interactions avec les inducteurs."
}
},
{
"@type": "Question",
"name": "Comment gérer l'induction du CYP2D6 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel d'ajuster les doses des médicaments affectés par l'induction."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des inhibiteurs du CYP2D6 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des inhibiteurs peuvent être utilisés pour contrer l'effet des inducteurs."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont souvent ajustés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antidépresseurs et les antipsychotiques sont souvent ajustés en cas d'induction."
}
},
{
"@type": "Question",
"name": "Y a-t-il des alternatives aux inducteurs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments non inducteurs peuvent être prescrits pour éviter l'interaction."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers et des dosages de médicaments sont nécessaires pour évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'induction ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent une inefficacité thérapeutique et des effets indésirables."
}
},
{
"@type": "Question",
"name": "L'induction peut-elle entraîner des hospitalisations ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des hospitalisations peuvent être nécessaires en cas de complications graves."
}
},
{
"@type": "Question",
"name": "Quels risques sont associés à l'induction ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des interactions médicamenteuses et des effets secondaires graves."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'induction ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est crucial d'ajuster les traitements et de surveiller les patients de près."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications à long terme peuvent inclure des effets résiduels sur le métabolisme."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'induction ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'utilisation de certains médicaments et des variations génétiques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il l'induction du CYP2D6 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut affecter le métabolisme et la réponse aux inducteurs."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie jouent-elles un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme l'alcool et le tabac peuvent influencer l'induction."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines variations génétiques peuvent augmenter le risque d'induction."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les interactions avec d'autres médicaments peuvent augmenter le risque d'induction."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 24/02/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Biostatistics & Epidemiology Core, Division of Health Services and Outcomes Research, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
Division of Developmental and Behavioral Sciences, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical Science, University of Nottingham, Malaysia Campus, Semenyih, Selangor, Malaysia.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Clinical Pharmacology Unit, Zealand University Hospital, Sygehusvej 10, 4000 Roskilde, Denmark.
Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada. r.tyndale@utoronto.ca.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. r.tyndale@utoronto.ca.
Department of Psychiatry, University of Toronto, 1 King's College Circle, Toronto, Ontario, M5S 1A8, Canada. r.tyndale@utoronto.ca.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
PharmGenetix GmbH, Niederalm, Austria.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Mental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Mental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Mental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Mental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Mental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK. e.bramon@ucl.ac.uk.
Institute of Psychiatry, Psychology and Neuroscience, King's College London and South London and Maudsley NHS Foundation Trust, London, UK. e.bramon@ucl.ac.uk.
Institute of Cognitive Neuroscience, University College London, London, UK. e.bramon@ucl.ac.uk.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
Department of Pharmacy, University of Oslo, Oslo, Norway.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
Patients with functional disorders (FD) often experience cognitive problems such as forgetfulness and distractibility alongside physical symptoms that cannot be attributed to a known somatic disease....
Test scores of cognitive tests and psychiatric rating scales of 100 outpatients diagnosed with a functional disorder were compared to a control group (n = 300) of patients with other diagnoses and to ...
Out of the 100 patients with functional disorders, 59 reported significant subjective cognitive symptoms. A moderate difference (d = 0.5-0.7) was found between the FD group mean and the population mea...
The findings of the study suggest that a decline in processing speed is a central feature in the cognitive profile of patients with functional disorders....
This article examines the role of uric acid (UA) in cognitive changes and neurodegeneration, focusing on its functions as an antioxidant and prooxidant. Research suggests that changes in serum UA leve...
Cognitive functioning in bipolar disorder is heterogeneous with evidence for multiple subgroups. However, cognitive subgroup change patterns over time remains unknown. While prior work suggests minima...
Participants diagnosed with bipolar disorder (I, II, NOS; n = 568) and unaffected controls (n = 234) completed baseline, one- and five-year neuropsychological assessments. Data reduction techniques we...
Results were consistent with bipolar disorder participants forming three subgroups with high (n = 209), mid (n = 259), and low (n = 100) cognition. These groups were associated with unique clinical ch...
These results demonstrate that cognition-based subgroups of bipolar disorder participants have minimal differences in their longitudinal course in relation to each other and with unaffected controls....
Recent research has proposed that certain aspects of psychosis, as experienced in, e.g., schizophrenia (SCZ), but also aspects of other cognitive conditions, such as autism spectrum disorders (ASD) an...
To conduct a systematic review to describe cognitive abilities in bipolar disorder (BD) in comparison to cognitive abilities in mild cognitive impairment (MCI) and dementia....
A literature search was performed with no year or language restrictions. The search yielded 1,461 articles, with 1,261 remaining after removal of duplicates, five of which were suitable for the system...
Analyses from our systematic review showed that euthymic individuals with BD present impairments in cognitive domains such as attention and executive functioning, motor skills, conceptual thinking, an...
Findings from our systematic review suggest that cognitive impairments in euthymic BD fall into a range between the impairments seen in MCI and those seen in dementia. More studies are needed to analy...
Cognitive deficits are prevalent in bipolar disorder even during the euthymic phase, having a negative impact on global functioning and quality of life. As such, more and more mental health profession...
The aim of this study was to assess the knowledge, attitudes and the rules of proceeding concerning primary health care (PHC) doctors in the field of screening diagnostics for cognitive disorders in e...
The study included 175 PHC doctors. A validated anonymous questionnaire was used. The survey was conducted using the PAPI (Paper and Pencil Interviews) and CAWI (Computer Assisted Web Interviews) meth...
The vast majority of the respondents (n=159; 91.4%) saw the advisability of screening for cognitive disorders in the age group >65 years of age, but only 53 subjects (30.29%) believed that these tests...
Polish GPs are aware of the necessity of screening for cognitive disorders in seniors. Currently, there are no mechanisms within primary health care system that would enable proper early screening for...
Functional cognitive disorders (FCDs) are a common cause of subjective and mild cognitive impairment. Isolated FCDs commonly present to the cognitive clinic, but examination of the nature of the sympt...
Cognitive impairment is a core feature of mood disorders and has been identified as an important treatment target. A better understanding of the factors contributing to cognitive impairment in mood di...
Studies in adult samples examining the relationship between objective cognitive function and reported childhood trauma in major depressive disorder and/or bipolar disorder (in-episode or euthymia) wer...
Seventeen studies met the criteria for inclusion (mood disorders N = 1723, healthy controls N = 797). Evidence for childhood trauma being related to poorer cognitive functioning was consistent across ...
Findings from this review suggest childhood trauma is associated with poorer cognitive functioning in people with mood disorders. Targeted interventions to improve cognition may be warranted for this ...
Extensive literature has explored the beneficial effects of music in age-related cognitive disorders (ACD), but limited knowledge exists regarding its impact on gene expression. We analyzed transcript...